In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer
Abstract Background Troglitazone (TGZ) is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist that has been investigated as a potential chemopreventive and chemotherapeutic agent. However, the antitumor efficacy and mechanisms of TGZ in pancreatic cancer have not been extensively inve...
Main Authors: | Megumi Fujita, Ai Hasegawa, Motohiro Yamamori, Noboru Okamura |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-07-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13046-017-0557-6 |
Similar Items
-
Troglitazone Impedes the Oligomerization of Sodium Taurocholate Cotransporting Polypeptide and Entry of Hepatitis B Virus Into Hepatocytes
by: Kento Fukano, et al.
Published: (2019-01-01) -
Troglitazone Stimulates the Insulin-induced Tetrahydrobiopterin Synthesis In Vascular Endothelial Cells
by: Ishii Masakazu, et al.
Published: (2000-11-01) -
Mechanistic Insights into Side Effects of Troglitazone and Rosiglitazone Using a Novel Inverse Molecular Docking Protocol
by: Katarina Kores, et al.
Published: (2021-02-01) -
The troglitazone derivative EP13 disrupts energy metabolism through respiratory chain complex I inhibition in breast cancer cells and potentiates the antiproliferative effect of glycolysis inhibitors
by: Claire Muller, et al.
Published: (2024-04-01) -
Knockdown of SEMA7A alleviates MPP+‐induced apoptosis and inflammation in BV2 microglia via PPAR‐γ activation and MAPK inactivation
by: Weinan Qi, et al.
Published: (2023-01-01)